The incidence of inflammatory bowel disease and rheumatoid arthritis have been in-creasing in recent years. These are both autoimmune diseases with similar pathogenesis involving com-plex interactions between immunity, inflammation, the intestinal microbiome and genetics. Epidemio-logical evidence suggests an increased risk of rheumatoid arthritis in patients with inflammatory bowel disease, which is often difficult to distinguish in the early stages of the disease because of the presence of arthritis symptoms in both cases. In terms of treatment, there are also drugs that cover both diseases. This article reviews the relationship between inflammatory bowel disease and rheumatoid arthritis in order to provide a basis for early identification and timely treatment of both.

1.Flynn S, Eisenstein S. Inflammatory bowel disease presentation and diagnosis[J]. Surg Clin North Am, 2019, 99(6): 1051-1062. DOI: 10.1016/j.suc.2019.08.001.

2.Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review[J]. JAMA, 2018, 320(13): 1360-1372. DOI:.10.1001/jama.2018.13103.

3.Ashrafi M, Kuhn KA, Weisman MH. The arthritis connection to inflammatory bowel disease (IBD): why has it taken so long to understand it?[J]. RMD open, 2021, 7(1): e001558. DOI: 10.1136/rmdopen-2020-001558.

4.Chen Y, Chen L, Xing C, et al. The risk of rheumatoid arthritis among patients with inflammatory bowel disease: a systematic review and meta-analysis[J]. BMC Gastroenterol, 2020, 20(1): 192. DOI: 10.1186/s12876-020-01339-3.

5.Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease[J]. J Immunol Res, 2019: 7247238. DOI: 10.1155/2019/7247238.

6.Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthri-tis via T helper 17 cells[J]. Immunity, 2010, 32(6): 815-827. DOI: 10.1016/j.immuni.2010.06.001.

7.Zaiss MM, Joyce Wu HJ, Mauro D, et al. The gut-joint axis in rheumatoid arthritis[J]. Nat Rev Rheu-matol, 2021, 17(4): 224-237. DOI: 10.1038/s41584-021-00585-3.

8.Schinocca C, Rizzo C, Fasano S, et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: an over-view[J]. Front Immunol, 2021, 12: 637829. DOI: 10.3389/fimmu.2021. 637829.

9.Maloy KJ. The Interleukin-23 / Interleukin-17 axis in intestinal inflammation[J]. J Intern Med, 2008, 263(6): 584-590. DOI: 10.1111/j.1365-2796.2008.01950.x.

10.Bamola VD, Ghosh A, Kapardar RK, et al. Gut microbial diversity in health and disease: experience of healthy Indian subjects and colon carcinoma and inflammatory bowel disease patients[J]. Microb Ecol Health Dis, 2017, 28(1): 1322447. DOI: 10.1080/16512235.2017.1322447.

11.Dong LN, Wang M, Guo J, et al. Role of intestinal microbiota and metabolites in inflammatory bowel disease[J]. Chin Med J (Engl), 2019, 132(13): 1610-1614. DOI: 10.1097/CM9.0000000000000290.

12.Alpizar-Rodriguez D, Lesker TR, Gronow A, et al. Prevotella copri in individuals at risk for rheumatoid arthritis[J]. Ann Rheum Dis, 2019, 78(5): 590-593. DOI: 10.1136/annrheumdis-2018-214514.

13.Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis[J]. Nat Immunol, 2021, 22(1): 10-18. DOI: 10.1038/s41590-020-00816-x.

14.Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis[J]. J Autoimmun, 2020, 110: 102400. DOI: 10.1016/j.jaut.2019.102400.

15.Lees CW, Barrett JC, Parkes M, et al. New IBD genetics: common pathways with other diseases[J]. Gut, 2011. 60(12): 1739-1753. DOI: 10.1136/gut.2009.199679.

16.Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 307-317. DOI: 10.1080/17474124.2019.1574569.

17.Littlejohn EA, Monrad SU. Early diagnosis and treatment of rheumatoid arthritis[J]. Prim Care, 2018, 45(2): 237-255. DOI: 10.1016/j.pop.2018.02.010.

18.Le Berre C, Roda G, Nedeljkovic Protic M, et al. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis[J]. Expert Opin Biol Ther, 2020, 20(4): 363-378. DOI: 10.1080/14712598.2019.1666101.

19.Lin YJ, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis[J]. Cells, 2020, 9(4): 880. DOI: 10.3390/cells9040880.

20.Jeong DY, Kim S, Son MJ, et al. Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review[J]. Autoimmun Rev, 2019, 18(5): 439-454. DOI: 10.1016/j.autrev.2019.03.002.

21.Berardicurti O, Ruscitti P, Pavlych V, et al. Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy[J]. Expert Rev Clin Pharmacol, 2020, 13(6): 593-604. DOI: 10.1080/17512433.2020.1772055.

22.Jiang X, Zeng J, Chen F, et al. Systematic review and meta-analysis on the efficacy of methotrexate in rheumatoid arthritis[J]. Ann Palliat Med, 2021, 10(10): 10652-10660. DOI: 10.21037/apm-21-2471.

23.Crouwel F, Simsek M, Mulder CJ, et al. Thioguanine therapy in inflammatory bowel diseases. A practi-cal guide[J]. J Gastrointestin Liver Dis, 2020, 29(4): 637-645. DOI: 10.15403/jgld-2765.

24.Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics[J]. Int J Mol Sci, 2021, 22(5): 2719. DOI: 10.3390/ijms22052719.

25.Melsheimer R, Geldhof A, Apaolaza I, et al. Remicade (infliximab): 20 years of contributions to science and medicine[J]. Biologics, 2019, 13: 139-178. DOI: 10.2147/BTT.S207246.

26.Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases[J]. Int Immunopharmacol, 2020, 80: 106210. DOI: 10.1016/j.intimp.2020.106210.

27.Azevedo A, Torres T. Tofacitinib: a new oral therapy for psoriasis[J]. Clin Drug Investig, 2018, 38(2): 101-112. DOI: 10.1007/s40261-017-0596-y.

28.Ferrante M, Sabino J. Efficacy of JAK inhibitors in ulcerative colitis[J]. J Crohns Colitis, 2020, 14(Supplement_2): S737-S745. DOI: 10.1093/ecco-jcc/jjz202.

29.Welty M, Mesana L, Padhiar A, et al. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis[J]. Curr Med Res Opin, 2020, 36(4): 595-606. DOI: 10.1080/03007995.2020. 1716701.